Oncotarget

Meta-Analysis:

Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis

Yajuan Lv _, Yong Hou, Bo Pan, Yuwan Ma, Paiyun Li, Lili Yu, Deguo Xu, Juanjuan Song, Heli Shang, Hongyan Wang and Yuan Tian

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:12376-12388. https://doi.org/10.18632/oncotarget.24212

Metrics: PDF 589 views  |   HTML 1880 views  |   ?  


Abstract

Yajuan Lv1,*, Yong Hou1,*, Bo Pan2,*, Yuwan Ma2,*, Paiyun Li2, Lili Yu1, Deguo Xu1, Juanjuan Song1, Heli Shang1, Hongyan Wang1 and Yuan Tian1

1Department of Radiation Oncology, Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, 250014, P.R. China

2Key Laboratory of Translational Research, Peking University Cancer Hospital and Institute, Beijing, 100142, China

*These authors contributed equally to this work

Correspondence to:

Yuan Tian, email: tytytianyuan@aliyun.com

Keywords: central catheters; PICC; CICC; thrombosis; mortality

Received: October 26, 2017     Accepted: December 05, 2017     Published: January 12, 2018

ABSTRACT

The risk of venous thrombosis and mortality associated with central catheter (PICC/CICC) for malignant tumor patients is not definite. So, we carried out a systematic review and meta-analysis to evaluate it. Among patients with comparing PICC with CICC, odds ratio (OR) or risk ratio (RR) was calculated with a random effect model meta-analysis. The result of the stratification analysis of 7 studies (PICC vs CICC) supported the theory that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs. 7 of 15 studies provided the information about the compared mortality rate of the patients. The result showed that CICCs were associated with a decrease in the odds ratio of thrombosis compared with PICCs (OR = 0.45, 95% CI:0.32–0.62, p < 0.0001, I2 = 0%,Tau2 = 0.00). Meta-analysis of 8 studies of 2639 patients showed that pharmacological deep vein thrombosis prophylaxis drugs could decrease the risk of mortality of malignant tumor patients with CICCs (RR = 0.58, 95% CI:0.48–0.71, Z = 5.32, p < 0.0001, I2 = 71%). We found that PICCs are associated with a raised risk of deep vein thrombosis, and pharmacological deep vein thrombosis prophylaxis drugs is a beneficial factor in decreasing the incidence of thrombosis, while warfarin may decrease the risk of mortality of malignant tumor patients with CICCs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24212